journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Cancer Institute. Monographs

journal
https://www.readbyqxmd.com/read/26063898/erratum-clinical-practice-guidelines-on-the-use-of-integrative-therapies-as-supportive-care-in-patients-treated-for-breast-cancer
#1
Heather Greenlee, Lynda G Balneaves, Linda E Carlson, Misha Cohen, Gary Deng, Dawn Hershman, Matthrew Mumber, Jane Perlmutter, Dugald Seely, Amanda Sen, Suzanna M Zick, Debu Tripathy
No abstract text is available yet for this article.
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063897/erratum-cancer-survival-an-overview-of-measures-uses-and-interpretation
#2
Angela B Mariotto
No abstract text is available yet for this article.
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063896/international-expert-consensus-on-primary-systemic-therapy-in-the-management-of-early-breast-cancer-highlights-of-the-fifth-symposium-on-primary-systemic-therapy-in-the-management-of-operable-breast-cancer-cremona-italy-2013
#3
Vito Amoroso, Daniele Generali, Thomas Buchholz, Massimo Cristofanilli, Rebecca Pedersini, Giuseppe Curigliano, Maria Grazia Daidone, Serena Di Cosimo, Mitchell Dowsett, Stephen Fox, Adrian L Harris, Andreas Makris, Lucia Vassalli, Andrea Ravelli, Maria Rosa Cappelletti, Christos Hatzis, Clifford A Hudis, Paolo Pedrazzoli, Anna Sapino, Vladimir Semiglazov, Gunter Von Minckwitz, Edda L Simoncini, Michael A Jacobs, Peter Barry, Thorsten Kühn, Sarah Darby, Kerstin Hermelink, Fraser Symmans, Alessandra Gennari, Gaia Schiavon, Luigi Dogliotti, Alfredo Berruti, Alberto Bottini
Expert consensus-based recommendations regarding key issues in the use of primary (or neoadjuvant) systemic treatment (PST) in patients with early breast cancer are a valuable resource for practising oncologists. PST remains a valuable therapeutic approach for the assessment of biological antitumor activity and clinical efficacy of new treatments in clinical trials. Neoadjuvant trials provide endpoints, such as pathological complete response (pCR) to treatment, that potentially translate into meaningful improvements in overall survival and disease-free survival...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063895/radiotherapy-issues-after-neoadjuvant-chemotherapy
#4
Kimberley S Mak, Jay R Harris
Radiotherapy (RT) is standard following neoadjuvant chemotherapy (NCT) and breast-conserving surgery. NCT leads to pathologic down-staging, allowing some patients to undergo breast-conserving therapy (BCT) instead of mastectomy. BCT can also be considered in select stage III patients who respond well to NCT. Clearly-negative surgical margins should be obtained in all patients undergoing BCT. RT is used selectively following NCT and mastectomy. Indications for RT have not been fully established; retrospective data and results from National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 currently form the basis for recommending RT...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063894/neoadjuvant-window-studies-of-metformin-and-biomarker-development-for-drugs-targeting-cancer-metabolism
#5
REVIEW
Simon R Lord, Neel Patel, Dan Liu, John Fenwick, Fergus Gleeson, Francesca Buffa, Adrian L Harris
There has been growing interest in the potential of the altered metabolic state typical of cancer cells as a drug target. The antidiabetes drug, metformin, is now under intense investigation as a safe method to modify cancer metabolism. Several studies have used window of opportunity in breast cancer patients before neoadjuvant chemotherapy to correlate gene expression analysis, metabolomics, immunohistochemical markers, and metabolic serum markers with those likely to benefit. We review the role metabolite measurement, functional imaging and gene sequencing analysis play in elucidating the effects of metabolically targeted drugs in cancer treatment and determining patient selection...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063893/rna-disruption-and-drug-response-in-breast-cancer-primary-systemic-therapy
#6
Kenneth Pritzker, Laura Pritzker, Daniele Generali, Alberto Bottini, Maria Rosa Cappelletti, Baoqing Guo, Amadeo Parissenti, Maureen Trudeau
BACKGROUND: As there is now evidence that switching clinical nonresponders early in primary systemic therapy to alternate treatment regimens can enhance survival in some breast cancer patients, the need for a robust intermediate endpoint that can guide treatment response across all tumor subtypes is urgent. Recently, chemotherapy drugs have been shown to induce a decrease in RNA quality in tumor cells from breast cancer biopsies in some patients at midtherapy, and that this has been associated with subsequent achievement of pathological complete response (pCR)...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063892/high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-transplantation-for-high-risk-primary-breast-cancer
#7
Paolo Pedrazzoli, Massimo Martino, Sara Delfanti, Daniele Generali, Giovanni Rosti, Marco Bregni, Francesco Lanza
BACKGROUND: The efficacy of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation for breast cancer (BC) has been an area of intense controversy among the medical oncology community. Over the last decade, due to the presentation of negative results from early randomized studies, this approach has not longer been considered an option by the vast majority of medical oncologists. This article is aimed to clarify what happened and where we are now in this not exhausted field...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063891/chemotherapy-and-cognitive-function-in-breast-cancer-patients-the-so-called-chemo-brain
#8
REVIEW
Kerstin Hermelink
Self-perceived problems of cognitive functioning after treatment for early-stage breast cancer have the potential to substantially affect the lives of patients. In the past two decades, neuropsychological studies have accumulated evidence of corresponding cognitive deficits that have mostly been attributed to neurotoxic effects of chemotherapy. Nevertheless, observations of impaired cognitive functioning already before the start of adjuvant or neoadjuvant chemotherapy question the singular role of chemotherapy for the causation of these deficits...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063890/effect-of-primary-letrozole-treatment-on-tumor-expression-of-mtor-and-hif-1%C3%AE-and-relation-to-clinical-response
#9
RANDOMIZED CONTROLLED TRIAL
Daniele Generali, Alfredo Berruti, Maria Rosa Cappelletti, Laura Zanotti, Giulia Brugnoli, Michela Forti, Francesca Bedussi, Maria Elena Vailati, Manuela Milani, Carla Strina, Mara Ardine, Sergio Aguggini, Giovanni Allevi, Giuseppina Ferrero, Ramona Bertoni, Alberto Bottini, Adrian L Harris, Stephen B Fox
INTRODUCTION: Recently the combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the aromatase inhibitor exemestane has been shown to double the progression-free survival rate in advanced breast cancer. However, the effect of the interrelated pathways of hypoxia-inducible factor-1α (HIF-1α) and mTOR signaling, both of which are associated with a more aggressive breast cancer phenotype and endocrine resistance, on response in the neoadjuvant setting is unknown...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063889/circulating-biomarkers-for-prediction-of-treatment-response
#10
Vera Cappelletti, Valentina Appierto, Paola Tiberio, Emanuela Fina, Maurizio Callari, Maria Grazia Daidone
For cancer management, predicting and monitoring response to treatment and disease progression longitudinally is crucial due to changes in tumor biology and therapy responsiveness over time. However, solid tumors are usually sampled only at time of initial diagnosis, as obtaining tissue biopsies is an invasive procedures with associated risks. Thus, there is a pressing need for approaches able to serially detect function-related reliable biomarkers reflecting treatment response and/or disease progression through easy noninvasive procedures, amenable for longitudinal analysis of tumor molecular features...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063888/ibc-as-a-rapidly-spreading-systemic-disease-clinical-and-targeted-approaches-using-the-neoadjuvant-model
#11
Shaheenah Dawood, Massimo Cristofanilli
Inflammatory breast cancer (IBC) is a rare and aggressive form of invasive breast cancer accounting for 2.5% of all breast cancer cases. It is characterized by rapid progression, younger age of onset as compared with other cancers, local and distant metastases, and lower overall survival. The multidisciplinary management of IBC includes neoadjuvant systemic chemotherapy, surgery, radiotherapy, and hormonal therapy in hormone receptor-positive disease. Pathological complete response represents an important prognostic factor suggesting IBC as the ideal in-vivo model for therapeutic development...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063887/neoadjuvant-model-for-testing-emerging-targeted-therapies-in-breast-cancer
#12
Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano
Neoadjuvant trials provide endpoints, such as pathological complete response (pCR) to treatment, that will potentially translate into meaningful improvements in overall survival and disease-free survival. Neoadjuvant trials need smaller sample sizes and are less expensive, and the endpoint of pCR is achieved in months, rather than years. For these reasons, the neoadjuvant setting is ideal for testing emerging targeted therapies in early breast cancer. Recently the US Food and Drug Administration has released a draft Guidance to Industry, outlining a pathway to accelerated approval for neoadjuvant breast cancer therapies using pCR...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063886/the-perfect-pathology-report-after-neoadjuvant-therapy
#13
Caterina Marchiò, Francesca Maletta, Laura Annaratone, Anna Sapino
Neoadjuvant therapy is increasingly being used in the management of breast cancer patients and, since comprehensive specimen handling and precise histological reporting is essential to assess the degree of response to therapy, histopathologists are acknowledged to play a key role in this multidisciplinary setting. However, as a matter of fact, only minimal guidelines for specimen handling are on record. This means that in every day routine practice it is not uncommon for oncologists to deal with pathology reports where important parameters are missing (such as formal comments about therapy response)...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063885/multiparametric-and-multimodality-functional-radiological-imaging-for-breast-cancer-diagnosis-and-early-treatment-response-assessment
#14
Michael A Jacobs, Antonio C Wolff, Katarzyna J Macura, Vered Stearns, Ronald Ouwerkerk, Riham El Khouli, David A Bluemke, Richard Wahl
Breast cancer is the second leading cause of cancer death among US women, and the chance of a woman developing breast cancer sometime during her lifetime is one in eight. Early detection and diagnosis to allow appropriate locoregional and systemic treatment are key to improve the odds of surviving its diagnosis. Emerging data also suggest that different breast cancer subtypes (phenotypes) may respond differently to available adjuvant therapies. There is a growing understanding that not all patients benefit equally from systemic therapies, and therapeutic approaches are being increasingly personalized based on predictive biomarkers of clinical benefit...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063884/neoadjuvant-chemotherapy-what-are-the-benefits-for-the-patient-and-for-the-investigator
#15
Daniel F Hayes, Anne F Schott
Neoadjuvant chemotherapy has several appealing potential benefits compared with classic adjuvant chemotherapy. Of these, the only proven benefit is to facilitate the surgical approach, either by converting an inoperable cancer to one that is operable, or by converting a patient who is felt to be a candidate for mastectomy to one who might be treated successfully with breast conserving therapy. Randomized trials comparing neoadjuvant chemotherapy with postoperative chemotherapy have failed to demonstrate prolongation of overall survival...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063883/neoadjuvant-treatment-approach-the-rosetta-stone-for-breast-cancer
#16
Daniele Generali, Mara Ardine, Carla Strina, Manuela Milani, Maria Rosa Cappelletti, Laura Zanotti, Michela Forti, Francesca Bedussi, Mario Martinotti, Vito Amoroso, Sandra Sigala, Edda Simoncini, Alfredo Berruti, Alberto Bottini
Breast cancer represents a heterogeneous group of diseases with varied biological features, behavior, and response to therapy; thus, management of breast cancer relies on the availability of robust predictive and prognostic factors to support therapy decision-making. Traditionally, neoadjuvant treatment for breast cancer was preserved for locally advanced, converting an inoperable to a surgical resectable cancer. Neoadjuvant trials, additionally, offer: 1) the opportunity to evaluate new treatment options in a faster way and with fewer patients than large adjuvant trials; 2) to identify and validate the prognostic and predictive value of a marker with its association with clinical outcome in relation to the administered treatment...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063882/comprehensive-review-on-the-surrogate-endpoints-of-efficacy-proposed-or-hypothesized-in-the-scientific-community-today
#17
REVIEW
Gunter von Minckwitz, Caterina Fontanella
An intermediate endpoint is a surrogate marker of treatment efficacy assessed earlier than the true outcome of interest. A suitable intermediate endpoint in neoadjuvant trials of specific breast cancer subtypes is pathological complete response (pCR) rate, defined as no invasive (+/-noninvasive) residual cancer in breast and nodes at surgery. On the basis of available evidence, Food and Drug Administration the US allowed to use of pCR as a surrogate endpoint for accelerated approval process. However, surrogacy to long-term outcome remains an unresolved issue...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063881/early-surrogate-markers-of-treatment-activity-where-are-we-now
#18
Marie Klintman, Mitchell Dowsett
The assessment of new therapies in the adjuvant setting in early breast cancer requires large numbers of patients and many years of follow-up for results to be presented. Therefore, the neoadjuvant study setting, which allows for early prediction of treatment response in smaller patient sets, has become increasingly popular. Ki67 is the most commonly used and extensively studied intermediate biomarker of treatment activity and residual risk in neoadjuvant trials on endocrine therapy, new biological therapies, and chemotherapy...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063880/recist-for-response-clinical-and-imaging-in-neoadjuvant-clinical-trials-in-operable-breast-cancer
#19
Vladimir Semiglazov
Although approximately 70% of breast cancer patients demonstrate a clinical response on neoadjuvant systemic therapy on physical examination or on anatomic radiographic imaging, only 3%-40% achieve a pathologic complete response (pCR). Magnetic resonance imaging (MRI) is superior to physical examination, ultrasound, and mammography in response evaluation during neoadjuvant systemic therapy. The accuracy of breast MRI to predict pCR has a moderate sensitivity, but high specificity. The accuracy of anatomic imaging to assess residual disease and predict pCR depended on anatomic radiographic imaging cancer subtypes...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/26063879/magnetic-resonance-imaging-digital-mammography-and-sonography-tumor-characteristics-and-tumor-biology-in-primary-setting
#20
David K Woolf, Anwar R Padhani, Andreas Makris
The use of imaging in the arena of primary treatment for breast cancer is gaining importance as a technique for assessing response to chemotherapy as well as assessing the underlying tumor biology. Both mammography and ultrasound have traditionally been used, in addition to clinical evaluation, to evaluate response to treatment although they have shed little light on the underlying biological processes. Functional magnetic resonance imaging techniques have the ability to assess response to treatments in addition to providing valuable information on changes in tumor perfusion, vascular permeability, oxygenation, cellularity, proliferation, and metabolism both at baseline and after treatment...
May 2015: Journal of the National Cancer Institute. Monographs
journal
journal
30508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"